CGM systems, like the FreeStyle Libre portfolio of products provide:
CGM = continuous glucose monitoring
Above Target Range (>180 mg/dL) 
In Target Range (70-180 mg/dL) 
Below Target Range (<70 mg/dL)
For illustrative purposes only. Not actual patient data.
Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
For patients with Type 2 diabetes using blood glucose monitoring (BGM), highs and lows aren't always easy to see¶6 .
For illustrative purposes only. Not actual patient data.
The use of fingerstick testing8 or A1c alone7 do not fully reveal glycemic patterns and trends,
but with FreeStyle Libre CGM systems, hidden glucose patterns are uncovered¶6.
Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third-party payor criteria apply.
Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
The product images are for illustrative purposes only.
* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.
† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.
‡ Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, when you see an error or “LO” or “HI” message, or no current glucose reading.
§ FreeStyle Libre 2 and 3 systems: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
ǁ FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
¶ Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.
# The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
** The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app.
†† The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView.
‡‡ Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User’s Manual for more information.
§§ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.
IIII The FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes age 4 and older.
¶¶ Self-monitoring of blood glucose.
References: 1. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55-73. https://doi.org/ 10.1007/s13300-016-0223-6. 2. Ajjan, Ramzi A., et al. "Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial." Diabetes and Vascular Disease Research 16, no. 4 (2019): 385-395. https://doi.org/10.1177/1479164119827456. 3. FreeStyle Libre 2 User's Manual. 4. FreeStyle Libre 3 User's Manual. 5. FreeStyle Libre 14 day User's Manual. 6. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no. 4 (2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393. 7. Battelino, Tadej, et al. "Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on Time in Range." Diabetes Care 42, no. 8 (2019): 1593-1603. https://doi.org/10.2337/dci19-0028. 8. Janapala, Rajesh Naidu, et al. "Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis." Cureus 11, no. 9 (2019): e5634. https://doi.org/10.7759/cureus.5634. 9. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 10. Wright, Eugene E., et al. "Use of Flash Continuous Glucose Monitoring Is Associated With A1c Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy." Diabetes Spectrum (2021): ds200069. https://doi.org/10.2337/ds20-0069. 11. Chaudhary, Arun. et al. "Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management." Frontiers In Endocrinology 8, no. 6 (2017). https://doi.org/10.3389/fendo.2017.00006.
ADC-42701 v3.0
Important Safety Information
FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855‑632‑8658 or FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-45115 v19.0
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
Do you wish to leave this site?
